# SLC35A2 expression is associated with HER2 expression in breast cancer

## TL;DR

This study found that SLC35A2 is overexpressed in breast cancer and linked to HER2 positivity, suggesting it could help predict outcomes in HER2-positive breast cancer patients.

## Contribution

The study identifies SLC35A2 as a potential prognostic marker specifically in HER2-positive breast cancer.

## Key findings

- SLC35A2 expression was significantly higher in breast cancer tissues than in non-neoplastic tissues.
- SLC35A2 expression was independently correlated with HER2 positivity in breast cancer patients.
- Low SLC35A2 expression was associated with better survival in HER2-positive breast cancer patients.

## Abstract

The role of SLC35A2 in breast cancer remains poorly understood, with limited available information on its significance. This study aimed to investigate the expression of SLC35A2 and clinicopathological variables in breast cancer patients. Immunohistochemical analysis of SLC35A2 protein was conductedon 40 adjacent non-neoplastic tissues and 320 breast cancer tissues. The study also assesed the association between SLC35A2 expression and breast cancer clinicopathological features of breast cancer, as well as its impact on overall survival. In comparison to adjacent non-neoplastic tissues, a significantly higher expression of SLC35A2 was observed in breast cancer tissues (P = 0.020), and this expression was found to be independently correlated with HER2 positivity (P = 0.001). Survival analysis indicated that patients with low SLC35A2 expression had a more favorable prognosis in HER2-positive subtype breast cancer (P = 0.017). These results suggest that SLC35A2 is overexpressed in breast cancer tissues compared to adjacent non-neoplastic tissues and may serve as a potential prognostic marker for HER2-positive subtype breast cancer. Furthermore, breast cancer patients with the HER2 positive subtype who exhibited decreased levels of SLC35A2 expression demonstrated improved long-term prognostic outcomes.